CTD Hikes on Niemann-Pick Treatment Trials

CTD Hikes on Niemann-Pick Treatment Trials

By: Dylan Sikes – AllPennyStocks.com News

Thursday, May 23, 2019

New developments were publicized Thursday in the effort to save lives, as Florida-based CTD Holdings Inc (OTC:CTDH) announced its first home-based infusion of its proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo, in a formal clinical trial.

Thursday’s news release said the trial is focusing on the long-term safety of Intravenous Trappsol® Cyclo in patients with Niemann-Pick Disease Type C (NPC-1) in the United States.

CEO Scott Fine says, "Today's infusion is a milestone for all who have supported CTD's clinical program from the very beginning. We are pleased to be able to provide home-based infusions to NPC patients even as we continue to gather data needed to support market registration of Trappsol® Cyclo for NPC."

CTD claims to be, again, quoting the release, “a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need.” 

While the volume wasn’t there by noon Thursday – only 10,000 shares – price action certainly turned heads, climbing 14 cents, or 20%, to 83.9 cents. 

 

 


Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon

Other Penny Stock Movers

Hmmm...Approved Drug, Bristol Myers Squibb as Partner and Tiny Market Cap
Bonanza of a Deal Sends Bonanza Shares Skyward
Acasti Surges on Year-End Figures
Aurion Reports Progress on Finnish Mine


Back to Top